A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver stress, prompting the company to pause enrollment and dosing while evaluating a new safety protocol. Elevate your perspective with NextTech News, where innovation meets insight. Discover the latest breakthroughs, get exclusive updates, and connect with a global network of future-focused thinkers. Unlock tomorrow’s trends today: read more, subscribe to our newsletter, and become part of the NextTech community at NextTech-news.com

Until this year, there were no treatments for transthyretin amyloidosis, a rare disease where misfolding transthyretin (TTR) proteins build up in the body’s tissues. | Current treatments for transthyretin amyloidosis interfere with RNA to inhibit protein production, but Intellia Therapeutics wants to intervene earlier, using a CRISPR-based treatment to edit the mutation underlying the disease.

Intellia’s CRISPR-based therapy maintained reductions in the levels of a misfolded protein in the nerves of patients with a rare disease called transthyretin amyloidosis. Functional improvement was also seen in the patients. The data come ...

Last night, Intellia filed a material event report ( 8-k ) with the SEC.  In there, they revealed a case of very high, grade 4 liver enzyme...

Intellia's stock sinks on gene therapy patient's raised enzyme levels, but analysts keep faith  Fierce Biotech

Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B  TipRanks

Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Potential Game-Changer?  TipRanks

The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. Both phase 3 studies of the candidate remain on hold as the biotech works to understand liver-related events seen in the trials and to develop a risk-mitigation plan.

Analysts Brush Off Intellia’s Adverse Event but Gene Therapy Safety Concerns Continue  BioSpace

Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Potential Game Changer  TipRanks

Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but analysts are keeping faith in the gene therapy’s wider safety profile.

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexi...

Patient in 80s dies after receiving Intellia Therapeutics' CRISPR therapy nex-z for ATTR. Death follows liver injury; exact cause unclear. CEO John Leonard announces trial pause.

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver stress, prompting the company to pause enrollment and dosing while evaluating a new safety protocol. Elevate your perspective with NextTech News, where innovation meets insight. Discover the latest breakthroughs, get exclusive updates, and connect with a global network of future-focused thinkers. Unlock tomorrow’s trends today: read more, subscribe to our newsletter, and become part of the NextTech community at NextTech-news.com

The Investor Relations website contains information about Intellia Therapeutics's business for stockholders, potential investors, and financial analysts.

Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer?  TipRanks

Breakthrough: Intellia's One-Time Gene Therapy Maintains 90% Disease Control After 2 Years in ATTR Study  Stock Titan

Intellia’s HAE gene therapy shows 98% attack reduction in three-year data  Investing.com India

Patient in 80s dies after receiving Intellia Therapeutics' CRISPR therapy nex-z for ATTR. Death follows liver injury; exact cause unclear. CEO John Leonard announces trial pause.

Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B  TipRanks

Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer?  TipRanks